Migraine
Conditions
Interventions
Rizatriptan Benzoate groups:Do not interfere with clinical diagnosis and treatment
Other drug treatment groups:Do not interfere with clinical diagnosis and treatment
Sponsors
the First Medical Center, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: • Male or female patients aged >= 14 • According to ICHD-3, it is mainly diagnosed as migraine • Have a history of migraine attacks for more than 1 year • Rizatraptan benzoate capsules are prescribed by doctors for the acute treatment of migraine • The written informed consent of the patient must be obtained before joining the group.
Exclusion criteria
Exclusion criteria: 1. Severely impaired language, vision, memory or cognitive function, affecting communication and understanding, or other patients who cannot complete the questionnaire or follow-up 2. Lack of equipment to complete questionnaires on the digital platform 3. Patients who are allergic to rizatraptan benzoate capsules or any excipient 4. Patients with severe liver damage or end-stage renal disease 5. Researchers believe that any situation that may affect the patient's participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Visual Analogue Scale (VAS) (0= painless, 10= severe pain) was used to assess the severity of the most severe headache after taking rizatriptan benzoate capsules and other migraine treatment drugs;The time when the headache begins to ease;The Medication Satisfaction Questionnaire (SM) scale assesses the satisfaction with pain relief;The SM scale assesses the satisfaction of functional recovery to normal; | — |
Secondary
| Measure | Time frame |
|---|---|
| PHQ-9;GAD-7; | — |
Countries
China
Contacts
Public ContactZhao Dong
the First Medical Center, Chinese PLA General Hospital
Outcome results
None listed